Articles

Comparison of Efficacy and Cost-Effectiveness of Filgrastim, tbo-Filgrastim, and Filgrastim-sndz in Patients with Cancer Receiving Myelosuppressive Chemotherapy and Patients with Severe Chronic Neutropenia

ASHP 2016

An analysis of the efficacy and cost-effectiveness of 3 colony-stimulating factors— filgrastim, tbo-filgrastim, and filgrastim-sndz—is presented. Read More ›

Personalizing Patient Management and Oral Adherence for the Oncology Patient

ASHP 2016

The role of the oncology pharmacist in promoting oral adherence for the oncology patient is discussed. Read More ›

Latest Developments in Short-Acting Granulocyte Colony-Stimulating Factor (G-CSF) Treatment Options: The First FDA-Approved Biosimilar, Zarxio® (filgrastim-sndz)

ASHP 2016

Biosimilarity between Zarxio and Neupogen is proven through PIONEER study results. Read More ›

IFCT-1001 CHIVA trial: A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)-associated advanced non-squamous non-small-cell lung cancer (NS-NSCLC)

ASCO 2016 – Lung Cancer

A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study

ASCO 2016 – Lung Cancer

A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13

ASCO 2016 – Lung Cancer

Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study

ASCO 2016 – Lung Cancer

An open-label phase 2 trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928)

ASCO 2016 – Lung Cancer

Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression

ASCO 2016 – Lung Cancer

Bayesian randomized trial comparing intensity-modulated radiation therapy versus passively scattered proton therapy for locally advanced non–small-cell lung cancer

ASCO 2016 – Lung Cancer

Articles

Page 116 of 143